{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:04:29Z","timestamp":1791396269482,"version":"4.3.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T00:00:00Z","timestamp":1444867200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1715-x","type":"journal-article","created":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T15:47:54Z","timestamp":1444924074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)"],"prefix":"10.1186","volume":"15","author":[{"given":"Xiao-jun","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-jiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-ming","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,15]]},"reference":[{"issue":"7","key":"1715_CR1","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557\u201376.","journal-title":"Gastroenterology"},{"issue":"4","key":"1715_CR2","first-page":"495","volume":"5","author":"YS Guan","year":"2006","unstructured":"Guan YS, Liu Y. Interventional treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006;5(4):495\u2013500.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"12","key":"1715_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00117-007-1587-4","volume":"47","author":"A Lubienski","year":"2007","unstructured":"Lubienski A, Simon M, Lubienski K, Gellissen J, Hoffmann RT, Jakobs TF, et al. [Update on chemoinfusion and chemoembolization treatments]. Radiologe. 2007;47(12):1097. \u20131106, 1108.","journal-title":"Radiologe"},{"issue":"7","key":"1715_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/j.1582-4934.2008.00563.x","volume":"13","author":"JF Chang","year":"2009","unstructured":"Chang JF, Chen PJ, Sze DY, Reid T, Bartlett D, Kirn DH, et al. Oncolytic virotherapy for advanced liver tumours. J Cell Mol Med. 2009;13(7):1238\u201347.","journal-title":"J Cell Mol Med"},{"issue":"5267","key":"1715_CR5","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1126\/science.272.5267.1470","volume":"272","author":"T Dobner","year":"1996","unstructured":"Dobner T, Horikoshi N, Rubenwolf S, Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 1996;272(5267):1470\u20133.","journal-title":"Science"},{"issue":"5","key":"1715_CR6","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1074\/jbc.M008218200","volume":"276","author":"CA Benedict","year":"2001","unstructured":"Benedict CA, Norris PS, Prigozy TI, Bodmer JL, Mahr JA, Garnett CT, et al. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and \u22122. J Biol Chem. 2001;276(5):3270\u20138.","journal-title":"J Biol Chem"},{"issue":"3","key":"1715_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.cgt.7700431","volume":"9","author":"N Habib","year":"2002","unstructured":"Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz RA, Sarraf C, et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 2002;9(3):254\u20139.","journal-title":"Cancer Gene Ther"},{"issue":"21","key":"1715_CR8","first-page":"6070","volume":"62","author":"T Reid","year":"2002","unstructured":"Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62(21):6070\u20139.","journal-title":"Cancer Res"},{"issue":"18","key":"1715_CR9","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3748\/wjg.v17.i18.2353","volume":"17","author":"Q He","year":"2011","unstructured":"He Q, Liu Y, Zou Q, Guan YS. Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma. World J Gastroenterol. 2011;17(18):2353\u20135.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1715_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cance","year":"2012","unstructured":"European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cance. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908\u201343.","journal-title":"J Hepatol"},{"issue":"2","key":"1715_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1245\/s10434-010-1321-8","volume":"18","author":"J Luo","year":"2011","unstructured":"Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18(2):413\u201320.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1715_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"9 Pt 2","key":"1715_CR13","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1016\/S1051-0443(07)61789-8","volume":"13","author":"DE Ramsey","year":"2002","unstructured":"Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13(9 Pt 2):S211\u2013221.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"1715_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000011863","volume":"55","author":"T Okusaka","year":"1998","unstructured":"Okusaka T, Okada S, Ishii H, Ikeda M, Nakasuka H, Nagahama H, et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology. 1998;55(4):276\u201383.","journal-title":"Oncology"},{"issue":"4","key":"1715_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000012115","volume":"58","author":"T Okusaka","year":"2000","unstructured":"Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 2000;58(4):293\u20139.","journal-title":"Oncology"},{"issue":"5286","key":"1715_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274(5286):373\u20136.","journal-title":"Science"},{"issue":"6","key":"1715_CR17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nm0697-639","volume":"3","author":"C Heise","year":"1997","unstructured":"Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3(6):639\u201345.","journal-title":"Nat Med"},{"issue":"3","key":"1715_CR18","first-page":"798","volume":"6","author":"I Ganly","year":"2000","unstructured":"Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6(3):798\u2013806.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1715_CR19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","volume":"19","author":"J Nemunaitis","year":"2001","unstructured":"Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19(2):289\u201398.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1715_CR20","first-page":"693","volume":"9","author":"D Makower","year":"2003","unstructured":"Makower D, Rozenblit A, Kaufman H, Edelman M, Lane ME, Zwiebel J, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res. 2003;9(2):693\u2013702.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1715_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/sj.gt.3301377","volume":"8","author":"D Kirn","year":"2001","unstructured":"Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 2001;8(2):89\u201398.","journal-title":"Gene Ther"},{"issue":"3","key":"1715_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/10430340150218369","volume":"12","author":"NA Habib","year":"2001","unstructured":"Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, Kelly M, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther. 2001;12(3):219\u201326.","journal-title":"Hum Gene Ther"},{"issue":"12","key":"1715_CR23","first-page":"1666","volume":"23","author":"ZJ Xia","year":"2004","unstructured":"Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng. 2004;23(12):1666\u201370.","journal-title":"Ai Zheng"},{"issue":"21","key":"1715_CR24","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/sj.gt.3301512","volume":"8","author":"T Reid","year":"2001","unstructured":"Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 2001;8(21):1618\u201326.","journal-title":"Gene Ther"},{"issue":"10","key":"1715_CR25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00432-009-0588-2","volume":"135","author":"C Zhong","year":"2009","unstructured":"Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135(10):1437\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"1715_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jmv.1890420406","volume":"42","author":"E Tabor","year":"1994","unstructured":"Tabor E. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol. 1994;42(4):357\u201365.","journal-title":"J Med Virol"},{"issue":"5","key":"1715_CR27","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.20203","volume":"39","author":"Z Pei","year":"2004","unstructured":"Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology. 2004;39(5):1371\u201381.","journal-title":"Hepatology"},{"issue":"17","key":"1715_CR28","first-page":"4369","volume":"59","author":"CM Vollmer","year":"1999","unstructured":"Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, et al. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. 1999;59(17):4369\u201374.","journal-title":"Cancer Res"},{"issue":"2","key":"1715_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429\u201342.","journal-title":"Hepatology"},{"issue":"1","key":"1715_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1148\/radiol.10101072","volume":"259","author":"J Luo","year":"2011","unstructured":"Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, et al. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. Radiology. 2011;259(1):286\u201395.","journal-title":"Radiology"},{"issue":"1","key":"1715_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0030-1247128","volume":"30","author":"M Sherman","year":"2010","unstructured":"Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30(1):3\u201316.","journal-title":"Semin Liver Dis"},{"issue":"5448","key":"1715_CR32","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","volume":"286","author":"E Marshall","year":"1999","unstructured":"Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286(5448):2244\u20135.","journal-title":"Science"},{"issue":"2","key":"1715_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/scientificamerican0200-36","volume":"282","author":"T Beardsley","year":"2000","unstructured":"Beardsley T. Gene therapy setback. Sci Am. 2000;282(2):36\u20137.","journal-title":"Sci Am"},{"issue":"2","key":"1715_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/jnci\/92.2.98","volume":"92","author":"S Jenks","year":"2000","unstructured":"Jenks S. Gene therapy death--\u201ceveryone has to share in the guilt\u201d. J Natl Cancer Inst. 2000;92(2):98\u2013100.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1715_CR35","first-page":"310","volume":"22","author":"ZY Yuan","year":"2003","unstructured":"Yuan ZY, Zhang L, Li S, Qian XZ, Guan ZZ. [Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer]. Ai Zheng. 2003;22(3):310\u20133.","journal-title":"Ai Zheng"},{"issue":"24","key":"1715_CR36","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","volume":"10","author":"W Lu","year":"2004","unstructured":"Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol. 2004;10(24):3634\u20138.","journal-title":"World J Gastroenterol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1715-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T21:22:35Z","timestamp":1498252955000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1715-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,15]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1715"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1715-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,15]]},"article-number":"707"}}